Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Intestinal Flora Affects Drug Response

By Kumamoto University | August 15, 2016

Antibacterial drugs cause changes in the intestinal flora. These changes have an influence on the capacity of the liver and kidneys to detoxify and eliminate therapeutic drugs due to large changes in the metabolizing and transport proteins. Credit: Dr. Sumio Ohtsuki

Intestinal flora has multiple influences on human health, but researchers have revealed that it is also likely to have an effect on the body’s response to drugs. Recent research from Kumamoto University in Japan strongly suggests that changes in the intestinal flora, caused by antibacterial and antibiotic drugs or individual differences between people, may have an effect on a person’s response to drugs including side effects. The research focused on the changes in proteins due to the condition of intestinal flora that affect the response to drugs in the liver and kidneys.

Antibacterial and antibiotic drugs are often prescribed for the treatment and prevention of bacterial infections and are often taken with therapeutic drugs to prevent recurrence of infection during treatment. Unfortunately, the drugs affect not only harmful bacteria, but also the naturally occurring bacteria within the intestine. To determine the effects of this influence on drug efficacy, Kumamoto University researchers investigated protein changes in the liver and kidney. Changes in these proteins have a great influence on drug efficacy and side effects since they are responsible for the metabolism and transport of many drugs, and are also affected by changes in the intestinal flora.

The research was conducted using three different groups of mice, an experimental group of germ-free mice which were free of intestinal bacteria since birth, a group of mice that had received antibacterial drugs for 5 consecutive days, and a control group of mice with naturally occurring intestinal flora. Researchers used proteomics, a large-scale analysis of proteins, to clarify changes in the amount of the proteins involved in drug metabolism and transport in the liver and kidney of the two experimental mouse groups.

“The most significant drug-metabolizing enzyme that decreased was cytochrome P450 2b10 (Cyp2b10),” said Professor Ohtsuki, who lead the research project. “Not only was the amount of the enzyme reduced nearly 96%, but the metabolic capacity of the drug in the liver was also reduced by approximately 82%. Cyp3a11, a similar type of enzyme was also reduced by about 88%. The human enzymes corresponding to these 2 enzymes, CYP2B6 and CYP3A4 are reported to be related to the metabolism of more than half of the pharmaceuticals on the market.”

Additionally, the breast cancer resistance protein (Bcrp1), a protein that transports many kinds of cancer drugs, was reduced by more than 50% in the livers of both experimental groups. Antibacterial drugs are sometimes prescribed to treat and prevent infection caused by bone marrow suppression, a side effect of cancer drugs.

“The results of this study show that many drugs may be affected by changes in the intestinal flora,” said Professor Ohtsuki. “In the future, if it is confirmed that similar mechanisms exist in humans, we expect our research to lead to optimal dosing and a reduction in drug side effects.”

This finding was posted on Molecular Pharmaceutics, on July 5th, 2016.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE